ArticlePloS one2011
Modelling the costs and effects of selective and universal hospital admission screening for methicillin-resistant Staphylococcus aureus.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 6 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review.BMJ global health · 2024Pooled it
- A systematic literature review of economic evaluation studies of interventions impacting antimicrobial resistance.Antimicrobial resistance and infection control · 2023Pooled it
- Simulation models for transmission of health care-associated infection: A systematic review.American journal of infection control · 2020Pooled it
- Impact of mupirocin resistance on the transmission and control of healthcare-associated MRSA.The Journal of antimicrobial chemotherapy · 2015Pooled it
- Modelling the transmission of healthcare associated infections: a systematic review.BMC infectious diseases · 2013Pooled it
- Transmission rates, screening methods and costs of MRSA--a systematic literature review related to the prevalence in Germany.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Pooled it
- Screening Strategies to Control Antibiotic-Resistant Bacteria: An Agent-Based Model.Antibiotics (Basel, Switzerland) · 2026Article
- Risk of Postoperative Infection in Total Knee Arthroplasty Patients with Preoperative Methicillin-ResistantJournal of clinical medicine · 2025Article
- Incidence and costs of hospitalized adult influenza patients in The Netherlands: a retrospective observational study.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Observational
- Unexpected Predictors of Antibiotic Resistance in Housekeeping Genes of Staphylococcus Aureus.ACM-BCB ... ... : the ... ACM Conference on Bioinformatics, Computational Biology and Biomedicine. ACM Conference on Bioinformatics, Computational Biology and Biomedicine · 2019Article
- Article
- Screening of methicillin-resistant Staphylococcus aureus nasal colonization among elective surgery patients in referral hospital in Indonesia.BMC research notes · 2018Article
- Multicenter Evaluation of the Xpert MRSA NxG Assay for Detection of Methicillin-Resistant Staphylococcus aureus in Nasal Swabs.Journal of clinical microbiology · 2018Article
- Cost Analysis of Universal Screening vs. Risk Factor-Based Screening for Methicillin-Resistant Staphylococcus aureus (MRSA).PloS one · 2016Article
- Reply to O'Riordan et al.Infection control and hospital epidemiology · 2015Article
- Cost-benefit analysis from the hospital perspective of universal active screening followed by contact precautions for methicillin-resistant Staphylococcus aureus carriers.Infection control and hospital epidemiology · 2015Article
- Analysis of MRSA-attributed costs of hospitalized patients in Germany.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014Article
- Article
- A regional informatics platform for coordinated antibiotic-resistant infection tracking, alerting, and prevention.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Article
- Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination.BMC medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundScreening at hospital admission for carriage of methicillin-resistant Staphylococcus aureus (MRSA) has been proposed as a strategy to reduce nosocomial infections. The objective of this study was to determine the long-term costs and health benefits of selective and universal screening for MRSA at hospital admission, using both PCR-based and chromogenic media-based tests in various settings. METHODOLOGY/PRINCIPAL
findingsA simulation model of MRSA transmission was used to determine costs and effects over 15 years from a US healthcare perspective. We compared admission screening together with isolation of identified carriers against a baseline policy without screening or isolation. Strategies included selective screening of high risk patients or universal admission screening, with PCR-based or chromogenic media-based tests, in medium (5%) or high nosocomial prevalence (15%) settings. The costs of screening and isolation per averted MRSA infection were lowest using selective chromogenic-based screening in high and medium prevalence settings, at $4,100 and $10,300, respectively. Replacing the chromogenic-based test with a PCR-based test costs $13,000 and $36,200 per additional infection averted, and subsequent extension to universal screening with PCR would cost $131,000 and $232,700 per additional infection averted, in high and medium prevalence settings respectively. Assuming $17,645 benefit per infection averted, the most cost-saving strategies in high and medium prevalence settings were selective screening with PCR and selective screening with chromogenic, respectively. CONCLUSIONS/SIGNIFICANCE: Admission screening costs $4,100-$21,200 per infection averted, depending on strategy and setting. Including financial benefits from averted infections, screening could well be cost saving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.